RRS® HA Long Lasting Secures Best Injectable Title at AMWC 2026

Recognizing Innovative Excellence: RRS® HA Long Lasting's Award at AMWC 2026

The prestigious AMWC (Aesthetic & Anti-Aging Medicine World Congress) has acknowledged Skin Tech Pharma Group's flagship product, RRS® HA LONG LASTING, as the Best Injectable in Skin Revitalization for 2026. This recognition highlights the product's role in transforming the landscape of aesthetic medicine and reinforces the company's standing within the Skin Builder category.

A Milestone in Aesthetic Medicine

Originally launched in 2021, RRS® HA LONG LASTING quickly established itself as a revolutionary solution for skin revitalization. With over one million treatments administered globally, it has demonstrated a remarkable safety record and consistent clinical performance that meets the growing demands for effective and natural-looking aesthetic treatments. As noted by Skin Tech Pharma's CEO, Márcio Rodrigues, this award represents a significant milestone and underscores the company's strategic commitment to scientific innovation and excellence in the field of aesthetic medicine.

What Makes RRS® HA Long Lasting Stand Out?

RRS® HA LONG LASTING is not merely a skin booster or a traditional dermal filler; rather, it artfully combines the best features of both. This unique injectable is composed of cross-linked hyaluronic acid paired with a protective buffer of 15 essential amino acids, which work synergistically to enhance skin structure, hydration, firmness, and texture. Unlike conventional products, it promises a nuanced lifting effect while effectively addressing fine lines and wrinkles.

The innovative formulation provides both immediate, visible results and progressive enhancements in skin quality, allowing for a more natural and gradual improvement. By targeting both skin restoration and volumetric enhancement, RRS® HA LONG LASTING represents a comprehensive approach to countering the signs of skin aging.

Clinical Insights and Expectations

According to Dr. Javed Hussain, a key opinion leader for Skin Tech Pharma Group, clinical applications of RRS® HA LONG LASTING consistently reveal significant improvements in skin texture, elasticity, and luminosity. The combination of hyaluronic acid and the amino acid buffer offers essential nutrients necessary for restoring natural dermal function, often diminished with aging. The results of this treatment not only surpass traditional skin boosters in terms of safety and effectiveness but also deliver a level of durability that sets a new standard.

Commitment to Quality and Sustainable Growth

With 30 years of innovation behind it, Skin Tech Pharma Group has established itself as a leader in aesthetic medicine, driven by rigorous research and development coupled with a keen understanding of market needs. The company has continually focused on developing high-quality, CE-marked medical devices and cosmeceuticals, which adhere to stringent safety and efficacy standards.

As it focuses on sustainable growth, its goal is to lead the industry towards higher standards of patient care while adapting to changing trends in aesthetic treatments. The recognition from AMWC 2026 for RRS® HA LONG LASTING affirms its mission to craft solutions that prioritize both aesthetic and health outcomes for patients.

Conclusion

Winning the AMWC 2026 award reaffirms RRS® HA LONG LASTING's role in advancing the field of aesthetic medicine, signifying its contribution to safer, effective, and natural-looking results for skin revitalization. As the aesthetic landscape continues to evolve, Skin Tech Pharma Group remains dedicated to innovation and excellence, fostering a new era of skin care solutions that empower individuals to achieve their desired aesthetic without compromising on safety or quality.